{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05864144",
            "orgStudyIdInfo": {
                "id": "SNS-101-2-1"
            },
            "organization": {
                "fullName": "Sensei Biotherapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
            "officialTitle": "A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-of-sns-anti-vista-monotherapy-and-in-combination-with-cemiplimab-in-patients-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-21",
            "studyFirstSubmitQcDate": "2023-05-08",
            "studyFirstPostDateStruct": {
                "date": "2023-05-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sensei Biotherapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Regeneron Pharmaceuticals",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.",
            "detailedDescription": "This is a first-in-human, Phase 1/2 open-label, multi-center, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.\n\nThis study is being conducted in three parts:\n\n* Part A: Phase 1 Monotherapy Dose Escalation and Dose Expansion (SNS-101 alone)\n* Part B: Phase 1 Combination Dose Escalation and Dose Expansion (SNS-101 in combination with cemiplimab)\n* Part C: Phase 2 Cohort Expansion (SNS-101 alone or in combination with cemiplimab)\n\nOnce the MTD/RP2D is determined, enrollment will expand to targeted tumor types:\n\n* Up to 10 patients with colorectal cancer (CRC) will be enrolled in the Monotherapy Dose Expansion at the monotherapy MTD/RP2D.\n\n  o Additional tumor types and doses may be considered upon consultation with the Sponsor.\n* Up to 30 patients with CRC, head and neck cancer (H\\&N), melanoma, and non-small cell lung cancer (NSCLC) will be enrolled in the Combination Dose Expansion at the combination MTD/RP2D.\n\n  * A minimum of 8 and a maximum of 10 CRC patients will be enrolled in the Combination Dose Expansion.\n  * Additional tumor types and doses may be considered upon consultation with the Sponsor."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult",
                "Advanced Solid Tumor",
                "Head and Neck Cancer",
                "Breast Cancer",
                "Colon Cancer",
                "Pancreatic Cancer",
                "Gastric Cancer",
                "Esophageal Cancer",
                "Prostate Cancer",
                "Uterine Cancer",
                "Cervix Cancer",
                "Ovarian Cancer",
                "Kidney Cancer",
                "Bladder Cancer",
                "Thyroid Cancer",
                "Melanoma",
                "Sarcoma",
                "Advanced Cancer",
                "Metastatic Cancer",
                "Refractory Cancer",
                "Non Small Cell Lung Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 169,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A - SNS-101 Monotherapy Dose Escalation and Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "SNS-101 IV alone every 21 days. Patients will initially enroll in dose escalation cohorts until the MTD/RP2D is determined.\n\nPatients will receive the MTD/RP2D for dose expansion.",
                    "interventionNames": [
                        "Drug: SNS-101 (anti-VISTA)"
                    ]
                },
                {
                    "label": "Part B - SNS-101 in combination with cemiplimab and Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "SNS-101 IV and cemiplimab IV every 21 days. Patients will initially enroll in dose escalation cohorts until the MTD/RP2D is determined.\n\nPatients will receive the MTD/RP2D for dose expansion.",
                    "interventionNames": [
                        "Drug: SNS-101 (anti-VISTA)",
                        "Drug: Cemiplimab"
                    ]
                },
                {
                    "label": "Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab",
                    "type": "EXPERIMENTAL",
                    "description": "SNS-101 IV alone or in combination with cemplimab IV every 21 days at the RP2D.",
                    "interventionNames": [
                        "Drug: SNS-101 (anti-VISTA)",
                        "Drug: Cemiplimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "SNS-101 (anti-VISTA)",
                    "description": "SNS-101 IV every 21 days.",
                    "armGroupLabels": [
                        "Part A - SNS-101 Monotherapy Dose Escalation and Dose Expansion",
                        "Part B - SNS-101 in combination with cemiplimab and Dose Expansion",
                        "Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cemiplimab",
                    "description": "Cemiplimab IV every 21 days.",
                    "armGroupLabels": [
                        "Part B - SNS-101 in combination with cemiplimab and Dose Expansion",
                        "Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events - Part A & B",
                    "description": "Incidence, nature and severity of treatment-related adverse events",
                    "timeFrame": "Day 1 through 90 days after the last dose"
                },
                {
                    "measure": "Determine the Recommended Phase 2 dose or maximum tolerated dose - Part A & B",
                    "description": "Incidence and nature of dose-limiting toxicities",
                    "timeFrame": "Approximately 15 months"
                },
                {
                    "measure": "Objective Response Rate (ORR) - Part C",
                    "description": "Measured by RECIST 1.1 and iRECIST",
                    "timeFrame": "Day 1 through study completion (approximately 1 year)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Determine pharmacokinetic profile (maximum concentration) of SNS-101 - Part A, B & C",
                    "description": "Measured by maximum concentration",
                    "timeFrame": "Day 1 through 30 days after the last dose"
                },
                {
                    "measure": "Determine pharmacokinetic profile (area under the curve) of SNS-101 - Part A, B & C",
                    "description": "Measured by area under the curve",
                    "timeFrame": "Day 1 through 30 days after the last dose"
                },
                {
                    "measure": "Determine pharmacokinetic profile (total clearance) of SNS-101 - Part A, B & C",
                    "description": "Measured by total clearance",
                    "timeFrame": "Day 1 through 30 days after the last dose"
                },
                {
                    "measure": "Determine pharmacokinetic profile (terminal half life) of SNS-101 - Part A, B & C",
                    "description": "Measured by serum terminal half-life",
                    "timeFrame": "Day 1 through 30 days after the last dose"
                },
                {
                    "measure": "Number of participants with anti-SNS-101 antibodies post-administration of SNS-101 - Part A, B & C",
                    "description": "Measured by anti-SNS-101 neutralizing anti-drug antibodies",
                    "timeFrame": "Day 1 through 30 days after the last dose"
                },
                {
                    "measure": "Objective Response Rate (ORR) - Part A & B",
                    "description": "Measured by RECIST 1.1 and iRECIST",
                    "timeFrame": "Day 1 through study completion (approximately 1 year)"
                },
                {
                    "measure": "Duration of Response (DoR) - Part A, B & C",
                    "description": "Measured by RECIST 1.1 and iRECIST",
                    "timeFrame": "Day 1 through study completion (approximately 1 year)"
                },
                {
                    "measure": "Disease Control Rate (DCR) - Part A, B & C",
                    "description": "Measured by RECIST 1.1 and iRECIST",
                    "timeFrame": "Day 1 through study completion (approximately 1 year)"
                },
                {
                    "measure": "Progression Free Survival - Part A, B and C",
                    "description": "Measured by RECIST 1.1 and iRECIST",
                    "timeFrame": "Day 1 through study completion - approximately 1 year (Part A, B & C)"
                },
                {
                    "measure": "Adverse Events - Part C",
                    "description": "Incidence, nature and severity of treatment-related adverse events",
                    "timeFrame": "Day 1 through study completion (approximately 1 year)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Histologically or cytologically documented locally advanced, unresectable or metastatic solid tumor.\n* Having received and failed or was intolerant to standard of care for advanced disease or not eligible for standard of care therapy with the following tumor types for patients in Phase 1 dose expansion cohorts:\n\n  1. Microsatellite Stable (MSS) CRC (both monotherapy and combination cohorts); no more than 3 lines of prior systemic therapy for metastatic disease.\n  2. H\\&N cancer (combination cohort only); no more than 2 lines of prior systemic therapy for metastatic disease.\n  3. Melanoma (combination cohort only); no more than 3 lines of prior systemic therapy for metastatic disease, including at least 1 prior treatment with a BRAF inhibitor for patients with a BRAF mutation.\n  4. NSCLC (combination cohort only); no more than 2 lines of prior systemic therapy for metastatic disease, including at least 1 prior treatment with a targeted therapy for patients with a mutation such as EGFR, ALK, KRAS, or RET.\n  5. Patients with H\\&N cancer, melanoma, and NSCLC must not have demonstrated primary refractory disease to a prior PD-1/PD-L1 agent where the best response to that therapy was progressive disease.\n\nAdditional tumor types and doses may be considered.\n\n* Measurable disease.\n* ECOG performance status 0 or 1.\n* Life expectancy of \u2265 3 months.\n* Willing to provide pre-treatment (archival or fresh) and on-treatment tumor biopsy samples.\n* Adequate organ function\n* Women of childbearing potential and fertile males with WOCBP partners must use highly effective contraception during the study and for 180 days after the study. Patients must agree not to donate eggs (ova, oocytes) or sperm during the study.\n\nKey Exclusion Criteria:\n\n* Use of anti-PD-1/PD-L1 targeting monoclonal antibody therapy, monoclonal antibody therapy, chemotherapy, biologic, investigational, or radiotherapy within 2 weeks of Cycle 1 Day 1.\n* Clinically significant unresolved toxicities from prior anticancer therapy.\n* Grade 3 or higher immune-related adverse event on prior PD-1/PD-L1 blockade or prior agents targeting stimulatory or co-inhibitory T cell receptor.\n* Known other previous/current malignancy requiring treatment within \u2264 2 years except for limited disease treated with curative intent, such as carcinoma in situ, squamous or basal cell skin carcinoma, or superficial bladder carcinoma.\n* Known asymptomatic or symptomatic brain metastasis or leptomeningeal disease.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n* Women who are pregnant or breastfeeding.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Janine McDermott",
                    "role": "CONTACT",
                    "phone": "781-392-5556",
                    "email": "jmcdermott@senseibio.com"
                },
                {
                    "name": "Joelle Lufkin",
                    "role": "CONTACT",
                    "email": "jlufkin@senseibio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ron Weitzman, MD",
                    "affiliation": "Sensei Biotherapeutics, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Icahn School of Medicine at Mt. Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Daniela Delbeau-Zagelbaum, MSN, APRN, AGNP-C, AGCNS-BC",
                            "role": "CONTACT",
                            "phone": "212-241-2066",
                            "email": "Daniela.Delbeau@mssm.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Sanford Cancer Center",
                    "status": "RECRUITING",
                    "city": "Sioux Falls",
                    "state": "South Dakota",
                    "zip": "57104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Steven Powell, MD",
                            "role": "CONTACT",
                            "phone": "605-328-8000"
                        },
                        {
                            "name": "Staci Vogel",
                            "role": "CONTACT",
                            "phone": "605-312-3336"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.54997,
                        "lon": -96.70033
                    }
                },
                {
                    "facility": "NEXT Oncology Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Erica Torres",
                            "role": "CONTACT",
                            "phone": "737-610-5180",
                            "email": "etorres@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics (START) San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Isabel Jimenez, RN, MSN",
                            "role": "CONTACT",
                            "phone": "210-593-5265",
                            "email": "isabel.jimenez@startsa.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "START Mountain Region",
                    "status": "RECRUITING",
                    "city": "West Valley City",
                    "state": "Utah",
                    "zip": "84119",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marie Asay",
                            "role": "CONTACT",
                            "phone": "801-907-4770",
                            "email": "marie.asay@startthecure.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69161,
                        "lon": -112.00105
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000007680",
                    "term": "Kidney Neoplasms"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000002583",
                    "term": "Uterine Cervical Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000002577",
                    "term": "Uterine Cervical Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16718",
                    "name": "Thyroid Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "asFound": "Uterine Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M10703",
                    "name": "Kidney Neoplasms",
                    "asFound": "Kidney Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M16723",
                    "name": "Thyroid Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5548",
                    "name": "Carcinoma, Renal Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "asFound": "Cervix Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5825",
                    "name": "Uterine Cervical Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4906",
                    "name": "Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "asFound": "Esophageal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000627974",
                    "term": "Cemiplimab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M302522",
                    "name": "Cemiplimab",
                    "asFound": "RAD",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}